Navigation Links
Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
Date:2/22/2010

2008 Net Income $5,328,141 $5,399,186 $7,479,816 $8,532,670 Loss (gain) in fair value of derivative liabilities $(6,687,085) $-- $(1,865,992) $-- Amortization of debt discount and debt issuance costs related to convertible debentures $5,751,934 $1,153,759 $8,020,587 $1,986,386 Adjusted Net Income $4,392,990 $6,552,945 $13,634,411 $10,519,056 Basic Weighted Average Number of Shares 10,983,405 9,771,883 10,744,648 9,770,615 Diluted Weighted Average Number of Shares** 15,065,301 14,148,318 14,829,605 14,173,463 Adjusted Diluted Earnings per Share $0.29 $0.46 $0.92 $0.74 ** Including outstanding options and warrants using treasury method of calculation plus the number of shares if converted from the convertible debt For more information, please contact: Jiangbo Pharmaceuticals, Inc. Ms. Elsa Sung, CFO Phone: +1-954-903-9378 x2 Email: elsasung@jiangbo.com Web: http://www.jiangbopharma.com CCG Investor Relations Ms. Lei Huang, Account Manager Phone: +1-646-833-3417 Email: lei.huang@ccgir.com Web: '/>"/>
SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related medicine technology :

1. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
2. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
3. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
4. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
5. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)...   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... announced that certain members of the executive management team ... be held September 8-10, 2014 in New ... Officer and President, is scheduled to present an overview ... a.m. ET on Wednesday, September 10, 2014. ...
(Date:8/27/2014)... Calif. , Aug. 27, 2014 Asterias ... U.S. Food and Drug Administration (FDA) to initiate a ... patients with complete cervical spinal cord injury.  The approved ... clinical study of the product, and is designed to ... in patients with complete cervical spinal cord injuries, the ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5
... Highlights from Avanafil Development Program Include: ... trials Comparative in-vitro selectivity of avanafil, sildenafil, ... post-prostatectomy population VIVUS, Inc. (NASDAQ: ... presented at the Sexual Medicine Society of North America (SMSNA) ...
... Campden Publishing Ltd today launched its medical and educational ... with the launch, Campden Health Communications has separately announced ... that enables its readers to upload video content directly ... magazine image. This is the first time the ,Aurasma, ...
Cached Medicine Technology:Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting 2Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting 3Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting 4Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting 5Campden Publishing Unveils new Med Comms Division and World-First Technology Licence 2
(Date:8/27/2014)... Los Angeles, CA (PRWEB) August 27, 2014 ... everyone. To do this, Jaha invested in creating the industry’s ... motivation by adding functions that no other apps possess. ... with a tracker that differentiates in three simple steps: locate, ... will launch on Tuesday, Aug 26, 2014 to garner support ...
(Date:8/27/2014)... The Global and China Maleic Anhydride ... current state of the Maleic Anhydride industry in Global ... of the industry, including definitions, applications and industry chain ... are provided with a focus on history, developments, trends ... the international and Chinese situation is also offered. Get ...
(Date:8/27/2014)... New Haven, CT (PRWEB) August 27, 2014 ... , CRN International is about to shed some light on ... exclusive research to members of the Brand Activation Association ... The 40-year-old marketing company polled hundreds of consumers to learn ... have the biggest impact on influencing a potential buying decision. ...
(Date:8/27/2014)... 2014 BCC Research ( http://www.bccresearch.com ) ... IMPLANTS AND REGENERATIVE PRODUCTS , the global market for ... billion by 2014-end to $42.2 billion by 2019, with ... 2014 to 2019. New technologies and an increasingly older ... the market. , While there are many conventional and ...
(Date:8/27/2014)... HealthDay Reporter TUESDAY, Aug. 26, 2014 ... for blood transfusions might also protect the brains of premature ... stimulates red blood cell production, appears to prevent brain damage ... Petra Huppi, a professor of pediatrics and newborn medicine at ... of whether EPO protects the brains of these children will ...
Breaking Medicine News(10 mins):Health News:Jaha, Inc. The Most Affordable Fitness Band in the Market Released on Kickstarter 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 4Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 5Health News:CRN Set To Release Poll Results On What Marketing Tactics Prompt Consumers To Buy 2Health News:Global Market for Advanced Orthopedic Technology to Reach $42.2 Billion in 2019; Biotechnological Advancements Driving the Market 2Health News:Global Market for Advanced Orthopedic Technology to Reach $42.2 Billion in 2019; Biotechnological Advancements Driving the Market 3Health News:Hormone Might Help Preemies' Brains 2Health News:Hormone Might Help Preemies' Brains 3
... ARBOR, Mich.---Persons with alcohol problems are finding comfort in ... shows. Among 1,910 people with any alcohol-related problems, ... researchers at the University of Michigan Health System and ... who used services from clergy also used professional services ...
... Today during the 88th General Session & Exhibition ... Spain, presenting author J. Meyle, Justus Liebig University, Giessen, ... Infection and Immune Evasion of Oral Carcinomas." ... oral cancers and periodontal disease. They achieved results by ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... long shadow. Those who survive the original cancer are ... new cancers, heart disease and stroke likely caused by ... more children are surviving cancer, many have long-term risks ...
... associated with cancer symptoms often unrecognized and ... telephone-based care management coupled with automated symptom monitoring, ... Indiana University School of Medicine. The Indiana ... calls with follow-up calls from the nurse care ...
... A report issued by the Program on International Health ... Health proposes a new research agenda to address the ... "The Pregnancy Intentions of HIV-Positive Women: Forwarding the ... urges a multi-disciplinary research approach to help HIV-positive women ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, ... the safety of controversial diabetes drug Avandia, members of the ... skeptical of much of the data presented. A decision ... The hearing has coincided with news that the drug,s ...
Cached Medicine News:Health News:Individuals confess alcohol abuse to clergy 2Health News:Childhood Cancer Survivors at Risk of Premature Death 2Health News:Childhood Cancer Survivors at Risk of Premature Death 3Health News:Help is on the phone: Reducing pain and depression of cancer 2Health News:Report proposes new research agenda on pregnancy intentions of HIV-positive women 2Health News:Report proposes new research agenda on pregnancy intentions of HIV-positive women 3Health News:FDA Panel Seems Skeptical Over Key Avandia Data 2Health News:FDA Panel Seems Skeptical Over Key Avandia Data 3Health News:FDA Panel Seems Skeptical Over Key Avandia Data 4
Instrument Cover for Vibratome....
These specialty razor blades are feather thin and very sharp. Most users have found an increased quality level in Vibratome sections with these blades....
This is a perfect tool for retrieving free floating sections from the Vibratome bath....
The care package includes a spare motor, fuse, Spare Fluorescent Bulb, additional Vibratome Feather Blades, Specimen Adhesive, Specimen Mounting Blocks, and a Specimen Tray....
Medicine Products: